XenoPort, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://xenoport.com
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01171313
- Locations
- 🇺🇸
XenoPort Clinical Site, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT00978016
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00914602
- Locations
- 🇺🇸
XenoPort Investigational Site, Bingham Farms, Michigan, United States
Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00833391
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT00817986
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT00748098
- Locations
- 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States
Prevention Study in Adult Patients Suffering From Migraine Headaches
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 526
- Registration Number
- NCT00742209
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT00643760
- Locations
- 🇺🇸
GSK Investigational Site, Vancouver, Washington, United States
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT00619476
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00617461
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
© Copyright 2024. All Rights Reserved by MedPath